#Indigo 7 technology code#

The name of the new technology device, substance or technology for a section “X” code is included as the main term.

New Technology section codes are easily found by looking in the ICD-10-PCS Index or the Tables. No additional codes from other sections in ICD-10-PCS are necessary for reporting as the specific procedure is described in the code title from section “X”. You will see other new technology codes with numbers from previous years that are still being paid. The new technology drugs for FY2022 will have the qualifier/seventh character of “7” since this is the seventh year of ICD-10-PCS.

#Indigo 7 technology update#

It is only used to indicate the year the code was created and all codes for that update year will have the same qualifier. This is a number that changes each year that new technology codes are added. The seventh character in section “X” is used to indicate the new technology group. The same root operation and body part values are used in section “X” as in other sections. Section “X” does not introduce any new coding concepts or unusual guidelines for correct coding and maintains continuity with the other sections in ICD-10-PCS. Section “X” is a separate place within ICD-10-PCS for certain new technology procedures (such as new technology drugs). 1, 2021 for a product that is approved for new-technology add-on payments beginning in FY 2022. CMS is also finalizing to discontinue NCTAP for discharges on or after Oct. CMS finalized to extend New COVID-19 Treatments Add-on Payment (NCTAP) for eligible products through the end of the fiscal year in which the COVID-19 PHE ends. FY2022 Medicare will make an add-on payment equal to the lesser of: (1) 75 percent medical product (65 % for new technology) of the costs of the new medical service or technology or (2) 75 percent of the amount by which the costs of the case exceed the standard DRG payment.ĬMS also finalized to extend New Technology Add-on Payments for 14 technologies that otherwise would be discontinued in FY 2022. CMS provides incremental payment (in addition to the DRG payment) for medical or new technologies that qualify for NTAP.